BPTS vs. AGRX, ARAV, MBIO, CYCC, NBY, BPTSY, ARDS, ONCO, VRPX, and CYTO
Should you be buying Biophytis stock or one of its competitors? The main competitors of Biophytis include Agile Therapeutics (AGRX), Aravive (ARAV), Mustang Bio (MBIO), Cyclacel Pharmaceuticals (CYCC), NovaBay Pharmaceuticals (NBY), Biophytis (BPTSY), Aridis Pharmaceuticals (ARDS), Onconetix (ONCO), Virpax Pharmaceuticals (VRPX), and Altamira Therapeutics (CYTO). These companies are all part of the "pharmaceutical preparations" industry.
Agile Therapeutics (NASDAQ:AGRX) and Biophytis (NASDAQ:BPTS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, community ranking, media sentiment, risk, profitability and institutional ownership.
Biophytis has a net margin of 0.00% compared to Biophytis' net margin of -73.83%.
10.9% of Agile Therapeutics shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 0.5% of Agile Therapeutics shares are held by company insiders. Comparatively, 3.7% of Biophytis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Agile Therapeutics has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, Biophytis has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500.
Agile Therapeutics received 418 more outperform votes than Biophytis when rated by MarketBeat users. However, 100.00% of users gave Biophytis an outperform vote while only 67.52% of users gave Agile Therapeutics an outperform vote.
Agile Therapeutics has higher revenue and earnings than Biophytis.
In the previous week, Agile Therapeutics had 1 more articles in the media than Biophytis. MarketBeat recorded 1 mentions for Agile Therapeutics and 0 mentions for Biophytis. Biophytis' average media sentiment score of 0.00 equaled Agile Therapeutics'average media sentiment score.
Agile Therapeutics currently has a consensus price target of $8.50, suggesting a potential upside of 2,163.65%. Biophytis has a consensus price target of $600.00, suggesting a potential upside of ∞. Given Agile Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Biophytis is more favorable than Agile Therapeutics.
Summary
Agile Therapeutics and Biophytis tied by winning 6 of the 12 factors compared between the two stocks.
Get Biophytis News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BPTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biophytis Competitors List
Related Companies and Tools
